{
  "GUIDELINE": {
    "type": "GUIDELINE",
    "pdf": "1756864558155_1608702.pdf",
    "input_text": "\n[第1页]\nBenralizumab for treating \nrelapsing or refractory \neosinophilic \ngranulomatosis with \npolyangiitis \nTechnology appraisal guidance \nPublished: 3 September 2025 \nwww.nice.org.uk/guidance/ta1096 \n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\nconditions#notice-of-rights).\n\n[第2页]\nYour responsibility \nThe recommendations in this guidance represent the view of NICE, arrived at after careful \nconsideration of the evidence available. When exercising their judgement, health \nprofessionals are expected to take this guidance fully into account, alongside the \nindividual needs, preferences and values of their patients. The application of the \nrecommendations in this guidance is at the discretion of health professionals and their \nindividual patients and do not override the responsibility of healthcare professionals to \nmake decisions appropriate to the circumstances of the individual patient, in consultation \nwith the patient and/or their carer or guardian. \nAll problems (adverse events) related to a medicine or medical device used for treatment \nor in a procedure should be reported to the Medicines and Healthcare products Regulatory \nAgency using the Yellow Card Scheme. \nCommissioners and/or providers have a responsibility to provide the funding required to \nenable the guidance to be applied when individual health professionals and their patients \nwish to use it, in accordance with the NHS Constitution. They should do so in light of their \nduties to have due regard to the need to eliminate unlawful discrimination, to advance \nequality of opportunity and to reduce health inequalities. \nCommissioners and providers have a responsibility to promote an environmentally \nsustainable health and care system and should assess and reduce the environmental \nimpact of implementing NICE recommendations wherever possible. \nBenralizumab for treating relapsing or refractory eosinophilic granulomatosis with\npolyangiitis (TA1096)\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\nconditions#notice-of-rights).\nPage 2 of\n23\n\n[第3页]\nContents \n1 Recommendations ..................................................................................................................\n4 \nWhy the committee made these recommendations ........................................................................\n5 \n2 Information about benralizumab ...........................................................................................\n6 \nMarketing authorisation indication ....................................................................................................\n6 \nDosage in the marketing authorisation .............................................................................................\n6 \nPrice ......................................................................................................................................................\n6 \nCarbon Reduction Plan .......................................................................................................................\n6 \n3 Committee discussion ...........................................................................................................\n7 \nThe condition .......................................................................................................................................\n7 \nClinical management ...........................................................................................................................\n8 \nClinical effectiveness ..........................................................................................................................\n9 \nEconomic model ..................................................................................................................................\n11 \nDiscontinuation ....................................................................................................................................\n13 \nTreatment-effect waning ....................................................................................................................\n16 \nUtility values ........................................................................................................................................\n16 \nOther factors .......................................................................................................................................\n18 \nCost-effectiveness estimates ............................................................................................................\n19 \nConclusion ...........................................................................................................................................\n20 \n4 Implementation .......................................................................................................................\n21 \n5 Evaluation committee members and NICE project team .................................................... 22 \nEvaluation committee members ........................................................................................................\n22 \nChair .....................................................................................................................................................\n22 \nNICE project team ...............................................................................................................................\n22 \nBenralizumab for treating relapsing or refractory eosinophilic granulomatosis with\npolyangiitis (TA1096)\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\nconditions#notice-of-rights).\nPage 3 of\n23\n\n[第4页]\n1 Recommendations \n1.1 \nBenralizumab as an add-on to standard care can be used, within its marketing \nauthorisation, as an option to treat relapsing or refractory eosinophilic \ngranulomatosis with polyangiitis (EGPA) in adults. It can only be used if the \ncompany provides it according to the commercial arrangement. \n1.2 \nStop benralizumab after 52 weeks if the EGPA has not responded. Response is: \n• a Birmingham Vasculitis Activity Score (BVAS) score of 0, and \n• a reduction in oral corticosteroid use, either: \n－ by 50% or more since starting benralizumab, or \n－ to 7.5 mg or less per day. \n1.3 \nThis recommendation is not intended to affect treatment with benralizumab that \nwas started in the NHS before this guidance was published. People having \ntreatment outside this recommendation may continue without change to the \nfunding arrangements in place for them before this guidance was published, until \nthey and their NHS healthcare professional consider it appropriate to stop. \nWhat this means in practice \nBenralizumab must be funded in the NHS in England for the condition and population \nin the recommendations, if it is considered the most suitable treatment option. \nBenralizumab must be funded in England within 90 days of final publication of this \nguidance. \nThere is enough evidence to show that benralizumab provides benefits and value for \nmoney, so it can be used routinely across the NHS in this population. \nNICE has produced tools and resources to support the implementation of this \nguidance. \nBenralizumab for treating relapsing or refractory eosinophilic granulomatosis with\npolyangiitis (TA1096)\n© NICE 2025. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-\nconditions#notice-of-rights).\nPage 4 of\n23\n\n[第5页]\nWhy the committee made these recommendations \nStandard care for relapsing or refractory EGPA is oral corticosteroids with or without \nimmunosuppressants. \nBenralizumab plus standard care has not been directly compared in a clinical trial with \nstandard care alone. But indirect comparisons suggest that benralizumab plus standard \ncare increases the likelihood of remission (having fewer or no symptoms of EGPA) and \nreduces relapse (having worse symptoms) compared with standard care alone. \nDespite uncertainties in the",
    "expected_output": {
      "doc_metadata": {
        "title": "Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis",
        "authors": "Not Found",
        "organization": "NICE",
        "publish_date": "3 September 2025",
        "year": "2025",
        "doi": "Not Found",
        "document_type": "Technology appraisal guidance",
        "sources": [
          "p1"
        ]
      },
      "scope": {
        "objective": "To provide NICE recommendations on benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) in adults, within its marketing authorisation and subject to a commercial arrangement.",
        "target_population": "Adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).",
        "sources": [
          "p4"
        ]
      },
      "recommendations": [
        {
          "id": "1.1",
          "text": "Benralizumab as an add-on to standard care can be used, within its marketing authorisation, as an option to treat relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) in adults. It can only be used if the company provides it according to the commercial arrangement.",
          "sources": [
            "p4"
          ]
        },
        {
          "id": "1.2",
          "text": "Stop benralizumab after 52 weeks if the EGPA has not responded. Response is:\n• a Birmingham Vasculitis Activity Score (BVAS) score of 0, and\n• a reduction in oral corticosteroid use, either:\n－ by 50% or more since starting benralizumab, or\n－ to 7.5 mg or less per day.",
          "sources": [
            "p4"
          ]
        },
        {
          "id": "1.3",
          "text": "This recommendation is not intended to affect treatment with benralizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop.",
          "sources": [
            "p4"
          ]
        }
      ],
      "key_findings": [
        {
          "finding": "Standard care for relapsing or refractory EGPA is oral corticosteroids with or without immunosuppressants.",
          "data": "Not Found",
          "sources": [
            "p5"
          ]
        },
        {
          "finding": "Benralizumab plus standard care has not been directly compared in a clinical trial with standard care alone.",
          "data": "Not Found",
          "sources": [
            "p5"
          ]
        },
        {
          "finding": "Indirect comparisons suggest that benralizumab plus standard care increases the likelihood of remission (having fewer or no symptoms of EGPA) and reduces relapse (having worse symptoms) compared with standard care alone.",
          "data": "Not Found",
          "sources": [
            "p5"
          ]
        },
        {
          "finding": "Benralizumab must be funded in the NHS in England for the condition and population in the recommendations, if it is considered the most suitable treatment option.",
          "data": "Not Found",
          "sources": [
            "p4"
          ]
        },
        {
          "finding": "Benralizumab must be funded in England within 90 days of final publication of this guidance.",
          "data": "90 days",
          "sources": [
            "p4"
          ]
        },
        {
          "finding": "Response definition for continuing treatment includes BVAS score of 0 and oral corticosteroid reduction criteria.",
          "data": "BVAS score of 0; oral corticosteroid reduction either by 50% or more since starting benralizumab, or to 7.5 mg or less per day; stop after 52 weeks if EGPA has not responded.",
          "sources": [
            "p4"
          ]
        }
      ],
      "extraction_notes": {
        "completeness": "High",
        "pages_with_key_content": [
          "p1",
          "p4",
          "p5"
        ]
      }
    }
  },
  "REVIEW": {
    "type": "REVIEW",
    "pdf": "1760091187079_1608702.pdf",
    "input_text": "\n[第1页]\n中国血液净化2025年10月第24卷第10期Chin J Blood Purif,October,2025,Vol.24,No.10\n·指南与共识·\n·\n·793\nYY/T 0793.4-2022《血液透析和相关治疗用液体的制备和质量管理\n第4部分：血液透析和相关治疗用透析液质量》标准解读\n柯军\n1\n叶晓燕\n2\n何晓帆\n1,3\n张云\n1\n【摘要】本文分析了我国医药行业标准YY/T 0793.4-2022《血液透析和相关治疗用液体的制备和质\n量管理第4部分：血液透析和相关治疗用透析液质量》与国际标准化组织(the International Organi-\nzation for Standardization，ISO)23500-5:2019的差异，并对主要条款进行解读。通过对标准的深入\n分析，帮助临床机构进一步提升血液透析和相关治疗用透析液的质量，对保障患者临床安全具有重要作\n用。\n【关键词】血液透析和相关治疗用透析液；微生物污染物；化学污染物\n中图分类号：R459.5\n文献标识码：A\ndoi:10.3969/j.issn.1671-4091.2025.10.001\nInterpretion of the standard YY/T 0793.4-2022 Preparation and quality management of fluids for hemo-\ndialysis and related therapies-Part 4: Quality of dialysis fluid for hemodialysis and related therapies\nKE Jun\n1, YE Xiao-yan\n2, HE Xiao-fan\n1，3, ZHANG Yun\n1 1Guang dong Medical Devices Quality Surveillance and\nTest Institute,Guangzhou 510663, China;\n2Guangzhou Vocational College of Technology &Business, Guang-\nzhou 511442, China;\n3Key Laboratory for Extracorporeal Circulation Devices,National Medical Products Ad-\nministration,Guangzhou 510663,China\nCorresponding author: KE Jun, Email:gzkj2003@163.com\n【Abstract】This article analyzes the differences between the standard YY/T 0793.4-2022 and the interna-\ntional standard (the International Organization for Standardization, ISO) 23500-5:2019, and provides an inter-\npretation of key clauses. Through in-depth analysis of the standards, it aims to help clinical institutions further\nimprove the quality of dialysis fluids used in hemodialysis and related therapies, which playing a crucial role\nin ensuring patient clinical safety.\n【Key words】Dialysis fluid for hemodialysis and related therapies; Microbiological contaminants;\nChemical contaminants\n在国际标准中，血液透析和相关治疗用透析液\n(dialysis solution)指由透析用水和浓缩物制得\n的液体，通常为含有电解质、缓冲液和葡萄糖的水溶\n液，在血液透析和血液透析滤过中用于和血液进行\n物质交换\n[1]。透析液与透析器配合使用，通过弥散\n(diffusion)、对流(convection)和超滤(ultrafil-\ntration)等物理机制清除尿毒症毒素(如尿素、肌\n酐、β2-微球蛋白)、纠正电解质紊乱(如高钾血症、\n高磷血症)及调节酸碱失衡(代谢性酸中毒)，达到内\n环境的平衡\n[2]。\n血液透析液主要包括标准透析液、超纯透析液\n和在线配制的置换液。血液透析液的质量直接关系\n到患者的治疗效果和生命安全，为确保透析液的安\n全性和有效性，各国都制定了严格的标准来规范其\n生产和质量检测。透析液直接参与血液透析治疗，\n因此不能含有毒、致热原、重金属等对机体有害的物\n质\n[3]。其中，微生物污染物和化学污染物的检测是\n透析液质量控制的重要环节。超纯透析液通常用于\n高通量血液透析治疗，置换液常用于血液滤过和血\n液透析滤过治疗，在线配制的置换液需达到静脉输\n液标准\n[3]。\n基金项目：广州市高校其他改革类项目(2024QTGG021)\n作者单位：510663 广州，\n1广东省医疗器械质量监督检验所机械化学室\n511442 广州，\n2广州科技贸易职业学院生物技术与健康学院\n510663 广州，\n3国家药品监督管理局体外循环器械重点实验室\n通信作者：柯军510663 广州，\n1广东省医疗器械质量监督检验所机械化学室Email:gzkj2003@163.com\n\n[第2页]\n中国血液净化2025年10月第24卷第10期Chin J Blood Purif,October,2025,Vol.24,No.10\n1\n标准介绍\n1.1\nYY(/T) 0793系列标准的组成\n《血液透析和相关治疗用液体的制备和质量管\n理》系列标准由1 项国家标准和4 项行业标准组成，\nYY/T 0793.4-2022是该系列行业标准中的第4部分。\n2019 年，国际标准化组织(the Internation-\nal Organization for Standardization，ISO)外科\n植入物技术委员会(ISO/TC150)心血管植入物和体\n外系统分技术委员会(SC2)(Technical Committee\nISO/TC150,Implants for surgery,Subcommittee\nSC2,Cardiovascular implants and extracorporeal\nsystems)编写了ISO 23500系列标准并发布实施，该\n系列标准由5 个部分组成，涉及血液透析和相关治\n疗用液体的制备和质量管理。我国标准化组织全国\n医用体外循环设备标准化技术委员会自2020 年起\n组织标准起草工作组结合我国实际情况修改采用\nISO 23500系列标准，形成了1项国家标准和4项行\n业标准[即YY(/T) 0793 系列标准]，自2022 年以来\n陆续发布实施。该系列标准涉及血液透析和相关治\n疗用液体的制备和质量管理，包括通用要求、血液透\n析和相关治疗用水处理设备、血液透析和相关治疗\n用水、血液透析和相关治疗用浓缩物、血液透析和相\n关治疗用透析液质量，系列标准信息详见表1\n[4-8]。\n1.2\nYY/T 0793.4-2022概况\nISO 23500系列标准由5部分组成，其中血液透\n析和相关治疗用透析液质量是该系列标准的第5部\n分即ISO 23500-5：2019《血液透析和相关治疗用液\n体的制备和质量管理第5部分：血液透析和相关治\n疗用透析液质量》。YY/T 0793.4-2022 标准修改采\n用了ISO 23500-5:2019，于2022 年7 月1 日首次发\n布，2023年7月1日实施\n[8]。\n在医疗机构中如果透析液的制备过程不规范，\n即使透析液制备用水及浓缩物符合YY 0793.2-\n2023和YY 0793.3-2023的标准要求，透析液中也可\n能出现微生物及污染物超标。YY/T 0793.4-2022\n适用于血液透析和相关治疗用透析液的质量管理，\n而YY 0793.3-2023 则规定了血液透析和相关治疗\n用浓缩物的技术要求(包括浓缩粉和浓缩液)。两者\n虽都属于YY/T 0793 系列标准，但在具体适用范围\n和关注点上存在差异。YY/T 0793.4-2022 和YY\n0793.3-2023 互为补充、相辅相成，通过实施这些标\n准，能有效提升血液透析治疗的临床安全性和有效\n性，降低患者并发症的风险，两者不能混淆使用\n[7,8]。\n1.3\nYY/T 0793.4-2022与ISO 23500-5:2019的主\n要差异\nISO 23500-5:2019 由ISO在2019年发布，欧洲\n标准化委员会(Comité Européen de Normalisa-\ntion，CEN)完整接受了该标准并在所有下属成员国\n中实施，形成了欧洲标准EN ISO 23500-5:2019。\n美国医疗器械促进协会(The Association for\nthe Advancement of Medical Instrumentation,\nAAMI)负责批准了相应的转换标准,经美国国家标准\n表1\n我国《血液透析和相关治疗用液体的制备和质量管理》系列标准信息表\n标准名称\n采标情况\n发布日期\n实施日期\nGB/T 43050-2023血液透析和相关治疗\nISO 23500-1:2019 Preparation and quality\n2023-09-07\n2025-04-01\n用液体的制备和质量管理通用要求\nmanagement of fluids for haemodialysis and\nrelated therapies-Part1: General\nrequirements,MOD\nYY/T 0793.1-2022血液透析和相关治\nISO 23500-2:2019 Preparation and quality\n2022-07-01\n2024-07-01\n疗用液体的制备和质量管理\n第1部\nmanagement of fluids for haemodialysis and\n分：血液透析和相关治疗用水处理设备\nrelated therapies-Part2: Water treatment\nequipment for haemodialysis applications\nand related therapies,MOD\nYY 0793.2-2023血液透析和相关治疗\nISO 23500-3:2019 Preparation and quality\n2023-11-22\n2026-12-01\n用液体的制备和质量管理\n第2部\nmanagement of fluids for haemodialysis and\n分：血液透析和相关治疗用水\nrelated therapies-Part3: Water for\nhaemodialysis and related therapies,MOD\nYY 0793.3-2023血液透析和相关治疗\nISO 23500-4:2019 Preparation and quality\n2023-06-20\n2025-07-01\n用液体的制备和质量管理\n第3部分：\nmanagement of fluids for haemodialysis and\n血液透析和相关治疗用浓缩物\nrelated therapies-Part4: Concentrates for\nhaemodialysis and related therapies,MOD\nYY/T 0793.4-2022血液透析和相关治\nISO 23500-5:2019 Preparation and quality\n2022-07-01\n2023-07-01\n疗用液体的制备和质量管理\n第4部\nmanagement of fluids for haemodialysis and\n分：血液透析和相关治疗用透析液质量\nrelated therapies-Part5: Quality of dialysis\nfluid for haemodialysis and related\ntherapies,MOD\n注：GB/T，推荐性国家标准；YY/T，推荐性医药行业标准；YY，强制性医药行业标准；MOD，修改采用。\n·\n·794\n\n[第3页]\n中国血液净化2025年10月第24卷第10期Chin J Blood Purif,October,2025,Vol.24,No.10\n学会(American National Standards Institute,\nANSI) 审核成为美国国家标准ANSI/AAMI/ISO\n23500-5:2019。欧盟和美国标准均与国际标准\nISO 23500-5:2019 保持一致，适用范围包括标准透\n析液、超纯透析液和置换液。我国血液透析滤过和\n血液滤过治疗用的置换液属于处方药，其配方需通\n过药品监管部门审批，按照药品标准生产和使用，因\n此YY/T 0793.4-2022的适用范围仅包括标准透析液\n及超纯透析液，不适用于置换液，YY/T 0793.4-2022\n中删除了置换液的相关条款(包括在线血液滤过或\n在线血液透析滤过的置换液、非在线配制的血液透\n析滤过和血液滤过的置换液)，这也是YY/T 0793.4-\n2022与ISO 23500-5:2019最重要的差异\n[8,9]。\n除此以外，YY/T 0793.4-2022 根据我国临床治\n疗用透析液的实际情况，对ISO 23500-5:2019的部\n分内容进行了适当的修改和补充。对于微生物污染\n的检测方法，YY/T 0793.4-2022 结合了我国医药行\n业实际情况，对检测方法进行了优化和细化，以提高\n检测结果的准确性和可靠性。对于化学污染物的检\n测方法，YY/T 0793.4-2022也根据我国的实际情况进\n行了相应的修改，检测方法可直接引用YY 0793.2-\n2023《血液透析和相关治疗用液体的制备和质量管\n理第2部分：血液透析和相关治疗用水》，避免了2份\n标准内容重复。这些差异体现了YY/T 0793.4-2022\n对我国透析液行业的针对性和适用性，从而更好的\n保障透析液质量安全。主要差异详见表2\n[8,9]。\n2\n标准解读\n2.1\n透析液中的微生物污染物及其检测方法\n脂多糖或内毒素导致的热原反应与革兰氏阴性\n菌有关。进一步研究显示革兰氏阴性水生细菌能在\n医院多种液体中迅速增殖，包括蒸馏水、去离子水、\n反渗透水及软化水等，这些液体曾作为血液透析系\n统供应用水\n[9]。透析液作为平衡盐溶液，在其生产\n过程中使用了上述液体，为这类细菌提供了适宜的\n生长环境。研究指出即便细菌污染水平较低，热原\n反应的发生率亦与透析液中细菌数量呈直接相关\n性\n[10]。因此，ISO 23500-5:2019 标准将透析液的微\n生物污染控制视为至关重要的环节。\nYY/T 0793.4-2022 中规定标准透析液的微生\n物计数总数应小于100 CFU/ml，内毒素含量应小于\n0.5 EU/ml；超纯透析液的微生物计数总数应小于\n0.1 CFU/ml，内毒素含量应小于0.03 EU/ml。ISO\n23500-5:2019 认为透析液中真菌(酵母菌和丝状真\n菌)的存在可能与细菌和内毒素的存在有关，但未给\n出此类污染物的最大限度值\n[11]。为与YY(/T)0793\n系列标准一致，按照《中华人民共和国药典》2020版\n的规定\n[12]，YY/T 0793.4-2022 明确微生物计数总数\n包括需氧菌、霉菌和酵母菌。\n此外YY/T 0793.4-2022 要求设定标准透析液\n的微生物限量和内毒素含量的干预水平(通常为微\n生物计数总数和内毒素最大允许含量的50%)。若\n标准透析液中的微生物总数超过干预水平，则应立\n即采取纠正措施(如消毒)降低微生物水平并重新检\n测。对于超纯透析液，若微生物计数总数和内毒素\n含量超过上限值，则应采取纠正措施将其降至可接\n受水平。\n与ISO 23500-5:2019 中给出的微生物培养方\n法不同，YY/T 0793.4-2022 引用了《中华人民共和\n国药典》2020版四部的微生物培养方法以符合我国\n国情\n[12]。2种方法的差异详见表3。\n需要说明的是这些方法仅提供细菌生物负载的\n相对指标，并非绝对测定值\n[11]。不同的培养基类型\n及培养周期可导致菌落浓度及回收的微生物类型产\n生差异\n[11,13]。有研究指出使用Reasoner’s 2A 琼脂\n培养基(Reasoner’s agar no.2,R2A)和胰酪大豆胨\n琼脂培养基(tryptic soy agar,TSA)对菌落数进行\n测定时，标准透析用水和标准透析液产生≥50 CFU/\nml 菌落数的生物负载并无显著性差异\n[13]。需要指\n出的是当需要更高灵敏度的检测方法时，应采用薄\n膜过滤法，\n《中华人民共和国药典》2020版四部对该\n方法做了详细规定\n[12]。\n与ISO 23500-5:2019 一致，YY/T 0793.4-2022\n表2\nYY/T 0793.4-2022与ISO 23500-5:2019的主要差异\n差异内容\nYY/T 0793.4-2022\nISO 23500-5:2019\n原因\n适用范围\n不含置换液\n包含置换液\n置换液在我国按处方药管理\n微生物要求\n标准透析液：微生物计数总数应小于\n标准透析液：细菌总数应小于\n按照《中华人民共和国药典》\n100 CFU/ml；\n100 CFU/ml；\n的规定，YY/T 0793.4-2022\n超纯透析液：微生物计数总数应小于\n超纯透析液：细菌总数应小于\n中的微生物计数包括需氧菌、\n0.1 CFU/ml\n0.1 CFU/ml\n霉菌和酵母菌\n微生物检测方法\n依据《中华人民共和国药典》增加微\n无具体检测方法\n中华人民共和国药典》中的微\n生物检测方法(微生物计数法)\n生物检测方法是法定方法\n化学污染物检测方法\n删除了ISO 23500-5:2019的附录B\n附录B给出了化学污染物最大\nYY 0793.2-2023中已给出详\n允许限量和推荐的检测方法\n细检测方法\n·\n·795\n\n[第4页]\n中国血液净化2025年10月第24卷第10期Chin J Blood Purif,October,2025,Vol.24,No.10\n中内毒素含量也采用鲎试剂法(limulus amoeby-\ncyte lysate，LAL)检测。\n2.2\n透析液中的化学污染物及其检测方法\n透析液是由透析用水和透析浓缩物制得的液\n体，通过透析液输送系统输送至透析器，因此透析液\n中化学污染物主要来源于透析用水和透析浓缩物。\n水质量控制是血液透析质量管理的基础，透析用水\n检测方法的正确性是获得客观准确结果的基础\n[14]。\nISO 23500-5:2019的附录B详细给出了透析用水化\n学污染物的种类、浓度上限值和分析方法，为避免重\n复，YY/T 0793.4",
    "expected_output": {
      "doc_metadata": {
        "title": "YY/T 0793.4-2022《血液透析和相关治疗用液体的制备和质量管理第4部分：血液透析和相关治疗用透析液质量》标准解读",
        "authors": "柯军; 叶晓燕; 何晓帆; 张云",
        "organization": "中国血液净化（Chin J Blood Purif）",
        "publish_date": "Not Found",
        "year": "2025",
        "doi": "10.3969/j.issn.1671-4091.2025.10.001",
        "document_type": "REVIEW",
        "sources": [
          "p1"
        ]
      },
      "scope": {
        "objective": "分析我国医药行业标准YY/T 0793.4-2022《血液透析和相关治疗用液体的制备和质量管理第4部分：血液透析和相关治疗用透析液质量》与ISO 23500-5:2019的差异，并对主要条款进行解读，以帮助临床机构进一步提升透析液质量，保障患者临床安全。",
        "target_population": "临床机构（血液透析和相关治疗用透析液质量管理相关人员）",
        "sources": [
          "p1"
        ]
      },
      "recommendations": [
        {
          "id": "R1",
          "text": "YY/T 0793.4-2022 要求设定标准透析液的微生物限量和内毒素含量的干预水平(通常为微生物计数总数和内毒素最大允许含量的50%)。",
          "sources": [
            "p3"
          ]
        },
        {
          "id": "R2",
          "text": "若标准透析液中的微生物总数超过干预水平，则应立即采取纠正措施(如消毒)降低微生物水平并重新检测。",
          "sources": [
            "p3"
          ]
        },
        {
          "id": "R3",
          "text": "对于超纯透析液，若微生物计数总数和内毒素含量超过上限值，则应采取纠正措施将其降至可接受水平。",
          "sources": [
            "p3"
          ]
        },
        {
          "id": "R4",
          "text": "需要指出的是当需要更高灵敏度的检测方法时，应采用薄膜过滤法，《中华人民共和国药典》2020版四部对该方法做了详细规定。",
          "sources": [
            "p3"
          ]
        }
      ],
      "key_findings": [
        {
          "finding": "我国标准YY/T 0793.4-2022修改采用ISO 23500-5:2019，并对主要条款进行解读，旨在帮助临床机构提升透析液质量、保障患者临床安全。",
          "data": "Not Found",
          "sources": [
            "p1"
          ]
        },
        {
          "finding": "YY(/T) 0793系列标准由1项国家标准和4项行业标准组成；YY/T 0793.4-2022是该系列行业标准中的第4部分。",
          "data": "Not Found",
          "sources": [
            "p2"
          ]
        },
        {
          "finding": "YY/T 0793.4-2022 于2022年7月1日首次发布，2023年7月1日实施。",
          "data": "2022-07-01发布；2023-07-01实施",
          "sources": [
            "p2"
          ]
        },
        {
          "finding": "YY/T 0793.4-2022 与ISO 23500-5:2019最重要的差异：我国标准适用范围仅包括标准透析液及超纯透析液，不适用于置换液，并删除了置换液相关条款；ISO/欧盟/美国标准适用范围包括标准透析液、超纯透析液和置换液。",
          "data": "Not Found",
          "sources": [
            "p3"
          ]
        },
        {
          "finding": "标准透析液微生物与内毒素限值：微生物计数总数应小于100 CFU/ml，内毒素含量应小于0.5 EU/ml。",
          "data": "<100 CFU/ml；<0.5 EU/ml",
          "sources": [
            "p3"
          ]
        },
        {
          "finding": "超纯透析液微生物与内毒素限值：微生物计数总数应小于0.1 CFU/ml，内毒素含量应小于0.03 EU/ml。",
          "data": "<0.1 CFU/ml；<0.03 EU/ml",
          "sources": [
            "p3"
          ]
        },
        {
          "finding": "为与YY(/T)0793系列标准一致并依据《中华人民共和国药典》2020版规定，YY/T 0793.4-2022 明确微生物计数总数包括需氧菌、霉菌和酵母菌。",
          "data": "Not Found",
          "sources": [
            "p3"
          ]
        },
        {
          "finding": "YY/T 0793.4-2022 的微生物培养方法引用《中华人民共和国药典》2020版四部的微生物培养方法以符合我国国情；与ISO 23500-5:2019给出的微生物培养方法不同。",
          "data": "Not Found",
          "sources": [
            "p3"
          ]
        },
        {
          "finding": "YY/T 0793.4-2022 中内毒素含量采用鲎试剂法（LAL）检测。",
          "data": "LAL法",
          "sources": [
            "p4"
          ]
        },
        {
          "finding": "透析液中化学污染物主要来源于透析用水和透析浓缩物；透析液通过透析液输送系统输送至透析器。",
          "data": "Not Found",
          "sources": [
            "p4"
          ]
        },
        {
          "finding": "水质量控制是血液透析质量管理的基础，透析用水检测方法的正确性是获得客观准确结果的基础。",
          "data": "Not Found",
          "sources": [
            "p4"
          ]
        },
        {
          "finding": "ISO 23500-5:2019附录B给出透析用水化学污染物的种类、浓度上限值和分析方法；YY/T 0793.4-2022删除了ISO 23500-5:2019的附录B，化学污染物检测方法可直接引用YY 0793.2-2023以避免重复。",
          "data": "Not Found",
          "sources": [
            "p3",
            "p4"
          ]
        },
        {
          "finding": "透析液在血液透析和血液透析滤过中用于和血液进行物质交换，通过弥散、对流和超滤等机制清除尿毒症毒素、纠正电解质紊乱及调节酸碱失衡。",
          "data": "示例毒素：尿素、肌酐、β2-微球蛋白；示例紊乱：高钾血症、高磷血症；示例失衡：代谢性酸中毒",
          "sources": [
            "p1"
          ]
        },
        {
          "finding": "血液透析液主要包括标准透析液、超纯透析液和在线配制的置换液；在线配制的置换液需达到静脉输液标准（背景描述）。",
          "data": "Not Found",
          "sources": [
            "p1"
          ]
        }
      ],
      "extraction_notes": {
        "completeness": "High",
        "pages_with_key_content": [
          "p1",
          "p2",
          "p3",
          "p4"
        ]
      }
    }
  }
}